TScan cuts 75% of staff, pauses ALLOHA-2 to focus on in vivo solid tumor program
The company also disclosed a Nasdaq bid-price deficiency notice and reported that all 13 tracked patients in ALLOHA Cohort C show complete donor chimerism.
TScan Therapeutics announced on September 2, 2026 that it is strategically reorganizing to prioritize its in vivo solid tumor program, advancing two product candidates to IND-enabling studies.1 The two candidates target PRAME and MAGE-A4, and the company expects to share preclinical data in Q1 2027 and file its first IND in Q3 2027, with plans to initiate Phase 1 development in Q4 2027.1
The company paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital needed to complete the trial.1 It will continue to track the 7 patients already enrolled on the treatment arm of ALLOHA-2, as well as the 13 patients in Cohort C of the Phase 1 ALLOHA study.1 In updated Cohort C data, all 13 of the patients currently being tracked show complete donor chimerism, including two patients who relapsed and then converted to complete donor chimerism after receiving either a third infusion of TSC-101 and/or additional targeted agents.1
As part of the restructuring, the strategic reorganization is expected to produce cumulative cost savings of $55.0 million through the end of 2027 and includes a workforce reduction of approximately 75%.1 The company said its available cash, cash equivalents and marketable securities as of June 30, 2026, will be sufficient to fund its planned operations into the fourth quarter of 2027.1 Related restructuring costs are expected to total approximately $4.1 million in employee-related costs, consisting primarily of pay continuation and related benefits.1
In leadership changes, CFO Jason A. Amello and CMO Chrystal Louis were terminated effective September 2, 2026, and Gavin MacBeath, Ph.D., the Company's Chief Executive Officer, assumed the duties of the principal financial officer and principal accounting officer of the Company.1
Separately, TScan disclosed that on August 27, 2026 it received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that the Company's voting common stock failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1).1 The company has an initial compliance period of 180 calendar days, or until February 23, 2027, to regain compliance.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.